Arcutis Biotherapeutics (ARQT) News Today $20.05 -0.66 (-3.19%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$19.42 -0.64 (-3.17%) As of 10/10/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARQT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Wealth Enhancement Advisory Services LLC Purchases Shares of 15,666 Arcutis Biotherapeutics, Inc. $ARQTOctober 11 at 3:06 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Arcutis Biotherapeutics (ARQT)October 8, 2025 | theglobeandmail.comArcutis Biotherapeutics (NASDAQ:ARQT) Hits New 1-Year High - Still a Buy?October 8, 2025 | marketbeat.comLarry Todd Edwards Sells 4,504 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) StockOctober 7, 2025 | insidertrades.comArcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $90,260.16 in StockOctober 6, 2025 | marketbeat.comArcutis Biotherapeutics stock rises after FDA approves eczema cream for young childrenOctober 6, 2025 | investing.comFDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5October 6, 2025 | markets.businessinsider.comArcutis Biotherapeutics Shares Rise After FDA Approves Eczema Cream for Young ChildrenOctober 6, 2025 | msn.comFDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5October 6, 2025 | globenewswire.comFishman Jay A Ltd. MI Purchases 23,000 Shares of Arcutis Biotherapeutics, Inc. $ARQTOctober 6, 2025 | marketbeat.comArcutis Biotherapeutics (ARQT): Evaluating Valuation as Upward Earnings Revisions Fuel Renewed Investor InterestOctober 4, 2025 | finance.yahoo.comArcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 10,000 SharesOctober 4, 2025 | insidertrades.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.2% Following Insider SellingOctober 4, 2025 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.2% After Insider SellingOctober 3, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 10,000 SharesOctober 3, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 20,739 SharesOctober 3, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 24,261 SharesOctober 3, 2025 | marketbeat.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comAMI Asset Management Corp Sells 94,839 Shares of Arcutis Biotherapeutics, Inc. $ARQTOctober 2, 2025 | marketbeat.comArcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025September 29, 2025 | globenewswire.comBiotech Leader Arcutis Is Breaking Out, Up Nearly 36% in 2025September 29, 2025 | msn.comArcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week High - What's Next?September 29, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 23, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 4.5% - What's Next?September 18, 2025 | marketbeat.comTriumph Capital Management Takes Position in Arcutis Biotherapeutics, Inc. $ARQTSeptember 18, 2025 | marketbeat.comArcutis Biotherapeutics announces new Zoryve data at EADV congressSeptember 17, 2025 | msn.comArcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology CongressSeptember 17, 2025 | globenewswire.comArcutis Biotherapeutics’ ZORYVE Wins 2025 Allure Best of Beauty Breakthrough Award for Innovation in DermatologySeptember 16, 2025 | quiverquant.comQAllure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough AwardSeptember 16, 2025 | globenewswire.comWoodline Partners LP Buys New Stake in Arcutis Biotherapeutics, Inc. $ARQTSeptember 15, 2025 | marketbeat.com20,652 Shares in Arcutis Biotherapeutics, Inc. $ARQT Bought by Invst LLCSeptember 15, 2025 | marketbeat.com36,313 Shares in Arcutis Biotherapeutics, Inc. $ARQT Purchased by Fred Alger Management LLCSeptember 13, 2025 | marketbeat.comTodd Watanabe Sells 9,625 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) StockSeptember 12, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Hits New 12-Month High - Here's WhySeptember 11, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE CreamSeptember 11, 2025 | msn.comInsider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 9,625 Shares of StockSeptember 11, 2025 | insidertrades.comArcutis Biotherapeutics (ARQT) Surges 31% In Last QuarterSeptember 10, 2025 | finance.yahoo.comArcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $583,860.80 in StockSeptember 10, 2025 | marketbeat.com55,205 Shares in Arcutis Biotherapeutics, Inc. $ARQT Purchased by Scientech Research LLCSeptember 10, 2025 | marketbeat.comArcutis Biotherapeutics Submits Supplemental New Drug Application to FDA For ZORYVESeptember 10, 2025 | insidermonkey.comArcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comArcutis Biotherapeutics (ARQT): Is the Stock’s Quiet Rally Signaling an Undervalued Opportunity?September 9, 2025 | finance.yahoo.com22,082 Shares in Arcutis Biotherapeutics, Inc. $ARQT Bought by Ieq Capital LLCSeptember 8, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. $ARQT Shares Sold by Cormorant Asset Management LPSeptember 6, 2025 | marketbeat.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comArcutis Biotherapeutics sybmits sNDA for ZORYVE Cream 0.3%September 3, 2025 | msn.comArcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comArcutis Biotherapeutics Submits Application for ZORYVE Cream as First Topical Treatment for Plaque Psoriasis in Children Ages 2 and UpSeptember 3, 2025 | quiverquant.comQArcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5September 3, 2025 | globenewswire.comParadigm Biocapital Advisors LP Acquires New Position in Arcutis Biotherapeutics, Inc. $ARQTSeptember 2, 2025 | marketbeat.com Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARQT Media Mentions By Week ARQT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼0.850.77▲Average Medical News Sentiment ARQT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼128▲ARQT Articles Average Week Get the Latest News and Ratings for ARQT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Arcutis Biotherapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies VRNA News Today RVMD News Today MRUS News Today RNA News Today GRFS News Today CYTK News Today RYTM News Today ABVX News Today CRSP News Today NUVL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
